The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
Identifieur interne : 00C868 ( Main/Exploration ); précédent : 00C867; suivant : 00C869The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
Auteurs : H. M Dodds [Australie] ; J. Robert [France] ; L. P Rivory [Australie]Source :
- Journal of Pharmaceutical and Biomedical Analysis [ 0731-7085 ] ; 1998.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Analyse quantitative, Homme, Spectrométrie.
English descriptors
- KwdEn :
- Alkaloid, Ampoule, Anal, Antineoplastic agent, Apci interface, Biological fluid, Biological samples, Biomed, Blood plasma, Campto, Camptosar, Chemical ionization, Chromatogram, Chromatogram extracts, Citric, Citric acid, Clinical stock, Degradation product, Dodds, Drug solutions, Elsevier science, Fluorescence detector, HPLC chromatography, Hplc, Human, Infusion, Infusion period, Infusion solution, Infusion solutions, Institut bergonie, Irinotecan, Irinotecan campto, Liquid chromatography, Mass spectrometry, Mobile phase, Pdp3, Pdp5, Pdps, Pharm, Photochemical degradation, Photodegradation, Photodegradation products, Poulenc rorer, Principal photodegradation products, Quantitative analysis, Retention time, Rivory, Routine administration, Spectrometry, Trace contaminants, Trace quantities, Uorescent, Urine.
- Teeft :
- Ampoule, Anal, Apci interface, Biological samples, Biomed, Campto, Camptosar, Chromatogram, Chromatogram extracts, Citric, Citric acid, Clinical stock, Dodds, Drug solutions, Elsevier science, Hplc, Infusion, Infusion period, Infusion solution, Infusion solutions, Institut bergonie, Irinotecan, Irinotecan campto, Liquid chromatography, Mobile phase, Pdp3, Pdp5, Pdps, Pharm, Photodegradation, Photodegradation products, Poulenc rorer, Principal photodegradation products, Retention time, Rivory, Routine administration, Spectrometry, Trace contaminants, Trace quantities, Uorescent, Urine.
Abstract
Abstract: A method for the detection of the photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®) was developed using high-performance liquid chromatography (HPLC) with fluorescence detection and HPLC/atmospheric pressure chemical ionisation/mass spectrometry (HPLC/APCI/MS). Remnants of infusion solution as well as samples of urine and plasma collected at the end of the infusion of CPT-11 to cancer patients were screened for the five principal known photodegradation products (PDPs) of CPT-11. The concurrent use of standards of the PDPs with ion-extract HPLC/APCI/MS chromatograms enabled the identification of trace quantities of two PDPs in most samples analysed. However, similar analyses of fresh clinical drug solutions revealed that the PDPs were not generated significantly by exposure to light during the infusion period, but were already present in the drug ampoules. Furthermore, this appears to be the source of traces of PDPs detectable in urine and plasma of patients rather than metabolism, per se.
Url:
DOI: 10.1016/S0731-7085(97)00256-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F29
- to stream Istex, to step Curation: 002F29
- to stream Istex, to step Checkpoint: 002225
- to stream Main, to step Merge: 00D905
- to stream PascalFrancis, to step Corpus: 006614
- to stream PascalFrancis, to step Curation: 006A48
- to stream PascalFrancis, to step Checkpoint: 006239
- to stream Main, to step Merge: 00DB26
- to stream Main, to step Curation: 00C868
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry</title><author><name sortKey="Dodds, H M" sort="Dodds, H M" uniqKey="Dodds H" first="H. M" last="Dodds">H. M Dodds</name></author><author><name sortKey="Robert, J" sort="Robert, J" uniqKey="Robert J" first="J" last="Robert">J. Robert</name></author><author><name sortKey="Rivory, L P" sort="Rivory, L P" uniqKey="Rivory L" first="L. P" last="Rivory">L. P Rivory</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FABA5F0E4241F8ABFB0DFE77F58612FC96917F2B</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0731-7085(97)00256-2</idno><idno type="url">https://api.istex.fr/document/FABA5F0E4241F8ABFB0DFE77F58612FC96917F2B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F29</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002F29</idno><idno type="wicri:Area/Istex/Curation">002F29</idno><idno type="wicri:Area/Istex/Checkpoint">002225</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002225</idno><idno type="wicri:doubleKey">0731-7085:1998:Dodds H:the:detection:of</idno><idno type="wicri:Area/Main/Merge">00D905</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0423710</idno><idno type="wicri:Area/PascalFrancis/Corpus">006614</idno><idno type="wicri:Area/PascalFrancis/Curation">006A48</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">006239</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006239</idno><idno type="wicri:doubleKey">0731-7085:1998:Dodds H:the:detection:of</idno><idno type="wicri:Area/Main/Merge">00DB26</idno><idno type="wicri:Area/Main/Curation">00C868</idno><idno type="wicri:Area/Main/Exploration">00C868</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry</title><author><name sortKey="Dodds, H M" sort="Dodds, H M" uniqKey="Dodds H" first="H. M" last="Dodds">H. M Dodds</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Deparment of Medicine, University of Queensland, Princess Alexandra Hospital, Woolloongabba, 4102 QLD</wicri:regionArea><wicri:noRegion>4102 QLD</wicri:noRegion></affiliation></author><author><name sortKey="Robert, J" sort="Robert, J" uniqKey="Robert J" first="J" last="Robert">J. Robert</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut Bergonié, 180 rue de Saint-Genès, Bordeaux, Cedex 33076</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Rivory, L P" sort="Rivory, L P" uniqKey="Rivory L" first="L. P" last="Rivory">L. P Rivory</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Deparment of Medicine, University of Queensland, Princess Alexandra Hospital, Woolloongabba, 4102 QLD</wicri:regionArea><wicri:noRegion>4102 QLD</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Pharmaceutical and Biomedical Analysis</title><title level="j" type="abbrev">PBA</title><idno type="ISSN">0731-7085</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">4–5</biblScope><biblScope unit="page" from="785">785</biblScope><biblScope unit="page" to="792">792</biblScope></imprint><idno type="ISSN">0731-7085</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0731-7085</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alkaloid</term><term>Ampoule</term><term>Anal</term><term>Antineoplastic agent</term><term>Apci interface</term><term>Biological fluid</term><term>Biological samples</term><term>Biomed</term><term>Blood plasma</term><term>Campto</term><term>Camptosar</term><term>Chemical ionization</term><term>Chromatogram</term><term>Chromatogram extracts</term><term>Citric</term><term>Citric acid</term><term>Clinical stock</term><term>Degradation product</term><term>Dodds</term><term>Drug solutions</term><term>Elsevier science</term><term>Fluorescence detector</term><term>HPLC chromatography</term><term>Hplc</term><term>Human</term><term>Infusion</term><term>Infusion period</term><term>Infusion solution</term><term>Infusion solutions</term><term>Institut bergonie</term><term>Irinotecan</term><term>Irinotecan campto</term><term>Liquid chromatography</term><term>Mass spectrometry</term><term>Mobile phase</term><term>Pdp3</term><term>Pdp5</term><term>Pdps</term><term>Pharm</term><term>Photochemical degradation</term><term>Photodegradation</term><term>Photodegradation products</term><term>Poulenc rorer</term><term>Principal photodegradation products</term><term>Quantitative analysis</term><term>Retention time</term><term>Rivory</term><term>Routine administration</term><term>Spectrometry</term><term>Trace contaminants</term><term>Trace quantities</term><term>Uorescent</term><term>Urine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Alcaloïde</term><term>Analyse quantitative</term><term>Anticancéreux</term><term>Camptothécine</term><term>Chromatographie HPLC</term><term>Dégradation photochimique</term><term>Détecteur fluorescence</term><term>Homme</term><term>Ionisation chimique</term><term>Irinotécan</term><term>Liquide biologique</term><term>Plasma sanguin</term><term>Produit dégradation</term><term>Pyrano indolizino quinoléine dérivé</term><term>Spectrométrie masse</term><term>Urine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Ampoule</term><term>Anal</term><term>Apci interface</term><term>Biological samples</term><term>Biomed</term><term>Campto</term><term>Camptosar</term><term>Chromatogram</term><term>Chromatogram extracts</term><term>Citric</term><term>Citric acid</term><term>Clinical stock</term><term>Dodds</term><term>Drug solutions</term><term>Elsevier science</term><term>Hplc</term><term>Infusion</term><term>Infusion period</term><term>Infusion solution</term><term>Infusion solutions</term><term>Institut bergonie</term><term>Irinotecan</term><term>Irinotecan campto</term><term>Liquid chromatography</term><term>Mobile phase</term><term>Pdp3</term><term>Pdp5</term><term>Pdps</term><term>Pharm</term><term>Photodegradation</term><term>Photodegradation products</term><term>Poulenc rorer</term><term>Principal photodegradation products</term><term>Retention time</term><term>Rivory</term><term>Routine administration</term><term>Spectrometry</term><term>Trace contaminants</term><term>Trace quantities</term><term>Uorescent</term><term>Urine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Analyse quantitative</term><term>Homme</term><term>Spectrométrie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: A method for the detection of the photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®) was developed using high-performance liquid chromatography (HPLC) with fluorescence detection and HPLC/atmospheric pressure chemical ionisation/mass spectrometry (HPLC/APCI/MS). Remnants of infusion solution as well as samples of urine and plasma collected at the end of the infusion of CPT-11 to cancer patients were screened for the five principal known photodegradation products (PDPs) of CPT-11. The concurrent use of standards of the PDPs with ion-extract HPLC/APCI/MS chromatograms enabled the identification of trace quantities of two PDPs in most samples analysed. However, similar analyses of fresh clinical drug solutions revealed that the PDPs were not generated significantly by exposure to light during the infusion period, but were already present in the drug ampoules. Furthermore, this appears to be the source of traces of PDPs detectable in urine and plasma of patients rather than metabolism, per se.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Dodds, H M" sort="Dodds, H M" uniqKey="Dodds H" first="H. M" last="Dodds">H. M Dodds</name></noRegion><name sortKey="Rivory, L P" sort="Rivory, L P" uniqKey="Rivory L" first="L. P" last="Rivory">L. P Rivory</name></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Robert, J" sort="Robert, J" uniqKey="Robert J" first="J" last="Robert">J. Robert</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00C868 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00C868 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FABA5F0E4241F8ABFB0DFE77F58612FC96917F2B
|texte= The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
}}
| This area was generated with Dilib version V0.6.33. |  |